Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Sule, Sangeeta ^a   Rosen, Antony ^a   Petri, Michelle ^a   Akhter, Ehtisham ^a   Andrade, Felipe ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; DEOXYRIBONUCLEASE; NUCLEIC ACID; RIBONUCLEASE;

ADULT; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; PHAGOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOSYNTHESIS; CELL SURVIVAL; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHAGOCYTOSIS;

ADULT; APOPTOSIS; CELL SURVIVAL; DEOXYRIBONUCLEASES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; NUCLEIC ACIDS; PHAGOCYTOSIS; RIBONUCLEASES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952646821     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017495     Document Type: Article

References (62)

1. Shlomchik MJ, Craft JE, Mamula MJ, (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1: 147-153.
2. Casciola-Rosen LA, Anhalt G, Rosen A, (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1317-1330.
3. Andrade F, Casciola-Rosen L, Rosen A, (2000) Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 26: 215-27.
4. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, et al. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest 101: 890-898.
5. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, et al. (1997) Immunosuppressive effects of apoptotic cells. Nature 390: 350-351.
6. Huynh ML, Fadok VA, Henson PM, (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109: 41-50.
7. Chen X, Doffek K, Sugg SL, Shilyansky J, (2004) Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol 173: 2985-2994.
8. Chung EY, Kim SJ, Ma XJ, (2006) Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res 16: 154-161.
9. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, et al. (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genetics 19: 56-59.
10. Paul E, Pozdnyakova OO, Mitchell E, Carroll MC, (2002) Anti-DNA autoreactivity in C4-deficient mice. Eur J Immunol 32: 2672-2679.
11. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, et al. (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 25: 177-181.
12. Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, et al. (2004) Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304: 1147-1150.
13. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, et al. (2002) Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 196: 135-140.
14. Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, et al. (2003) Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 48: 1602-1611.
15. Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, et al. (2005) Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 52: 642-650.
16. Du Clos TW, Zlock LT, Hicks PS, Mold C, (1994) Decreased autoantibody levels and enhanced survival of (NZB x NZW) F1 mice treated with C-reactive protein. Clin Immunol Immunopathol 70: 22-27.
17. Ren Y, Tang J, Mok MY, Chan AW, Wu A, et al. (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48: 2888-2897.
18. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, et al. (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41: 1241-1250.
19. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, et al. (2002) Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 46: 191-201.
20. Hepburn AL, Lampert IA, Boyle JJ, Horncastle D, Ng WF, et al. (2007) In vivo evidence for apoptosis in the bone marrow in systemic lupus erythematosus. Ann Rheum Dis 66: 1106-1109.
21. Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG, (2006) Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 65: 57-63.
22. Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, et al. (2005) Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 4: 189-194.
23. Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, et al. (1998) Apoptotic cell clearance in systemic lupus erythematosus- I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 41: 205-214.
24. Furukawa F, Kashihara-Sawami M, Lyons MB, Norris DA, (1990) Binding of antibodies to the extractable nuclear antigens of SS- A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol 94: 77-85.
25. LeFeber WP, Norris DA, Ryan SR, Huff JC, Lee LA, et al. (1984) Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 74: 1545-1551.
26. Casciola-Rosen L, Rosen A, (1997) Ultraviolet light-induced keratinocyte apoptosis: A potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 6: 175-180.
27. Andrade F, Casciola-Rosen LA, Rosen A, (2005) Generation of novel covalent RNA-protein complexes in cells by ultraviolet B irradiation: implications for autoimmunity. Arthritis Rheum 52: 1160-1170.
28. Marshak-Rothstein A, (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835.
29. Liou LB, (2003) Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels. Clin Exp Rheumatol 21: 437-444.
30. Sullivan KE, Suriano A, Dietzmann K, Lin J, Goldman D, et al. (2007) The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus. Clin Immunol 123: 74-81.
31. Liou LB, (2001) Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 19: 515-523.
32. Malave I, Searles RP, Montano J, Williams RC Jr, (1989) Production of tumor necrosis factor/cachectin by peripheral blood mononuclear cells in patients with systemic lupus erythematosus. Int Arch Allergy Appl Immunol 89: 355-361.
33. Meijer C, Huysen V, Smeenk RT, Swaak AJ, (1993) Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 2: 359-365.
34. Jones BM, Liu T, Wong RW, (1999) Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production with disease activity. Autoimmunity 31: 117-124.
35. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, et al. (2002) Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 11: 102-108.
36. Robak E, Sysa-Jedrzejewska A, Dziankowska B, Torzecka D, Chojnowski K, et al. (1998) Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz) 46: 375-380.
37. Maury CP, Teppo AM, (1989) Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 32: 146-150.
38. Robak E, Smolewski P, Wozniacka A, Sysa-Jedrzejowska A, Stepien H, et al. (2004) Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus. Eur Cytokine Netw 15: 222-230.
39. Horwitz DA, Wang H, Gray JD, (1994) Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: increased interleukin-2 but not interleukin-4 mRNA. Lupus 3: 423-428.
40. Malide D, Russo P, Bendayan M, (1995) Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 26: 558-564.
41. Studnicka-Benke A, Steiner G, Petera P, Smolen JS, (1996) Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35: 1067-1074.
42. Aringer M, Smolen JS, (2005) Cytokine expression in lupus kidneys. Lupus 14: 13-18.
43. Lee YH, Harley JB, Nath SK, (2006) Meta-analysis of TNF-alpha promoter-308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 14: 364-371.
44. Zou YF, Feng XL, Tao JH, Su H, Pan FM, et al. (2010) Meta-analysis of TNF-alpha promoter-308A/G polymorphism and SLE susceptibility in Asian populations. Rheumatol Int 2010 Mar 24. [Epub ahead of print].
45. Zou YF, Feng XL, Pan FM, Su H, Tao JH, et al. (2010) Meta-analysis of TNF-alpha promoter- 238A/G polymorphism and SLE susceptibility. Autoimmunity 43: 264-274.
46. Wu X, Peng SL, (2006) Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 54: 336-342.
47. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, et al. (2006) Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428.
48. Kelley J, Johnson MR, Alarcon GS, Kimberly RP, Edberg JC, (2007) Variation in the relative copy number of the TLR7 gene in patients with systemic lupus erythematosus and healthy control subjects. Arthritis Rheum 56: 3375-3378.
49. Shen N, Fu Q, Deng Y, Qian X, Zhao J, et al. (2010) Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 107: 15838-15843.
50. Demirci FY, Manzi S, Ramsey-Goldman R, Kenney M, Shaw PS, et al. (2007) Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol 34: 1708-1711.
51. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, et al. (2006) Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 54: 3601-3611.
52. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, et al. (2010) Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 159: 11-22.
53. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, et al. (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40: 1059-1061.
54. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40: 1062-1064.
55. Lemay S, Mao C, Singh AK, (1996) Cytokine gene expression in the MRL/lpr model of lupus nephritis. Kidney Int 50: 85-93.
56. Boswell JM, Yui MA, Burt DW, Kelley VE, (1988) Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 141: 3050-3054.
57. Jacob CO, McDevitt HO, (1988) Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 331: 356-358.
58. Shakoor N, Michalska M, Harris CA, Block JA, (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579-580.
59. Charles PJ, Smeenk RJ, De JJ, Feldmann M, Maini RN, (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43: 2383-2390.
60. Aringer M, Graninger WB, Steiner G, Smolen JS, (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50: 3161-3169.
61. Kashiwa H, Wright SC, Bonavida B, (1987) Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF). J Immunol 138: 1383-1390.
62. Steinbach F, Henke F, Krause B, Thiele B, Burmester GR, et al. (2000) Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility. Ann Rheum Dis 59: 283-288.